Pavel Bochkov
Overview
Explore the profile of Pavel Bochkov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdullaev S, Shatokhin M, Sychev I, Krasnov A, Bochkov P, Tuchkova S, et al.
Drug Metab Pers Ther
. 2025 Feb;
PMID: 39940086
Objectives: The clinical outcomes of tamsulosin therapy for LUTS/BPH patients vary, with up to one-third of patients reporting unsatisfactory results. Enhancing the effectiveness and safety of tamsulosin therapy for LUTS/BPH...
2.
Pakhomova A, Pershina O, Bochkov P, Ermakova N, Pan E, Sandrikina L, et al.
Life (Basel)
. 2023 Sep;
13(9).
PMID: 37763335
Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease, characterized by progressive parenchymal fibrosis and respiratory failure. In a model of bleomycin-induced pulmonary fibrosis,...
3.
Baturina O, Andreev D, Fedina L, Mirzaev K, Ivashchenko D, Ryzhikova K, et al.
Pharmacology
. 2022 Jan;
107(3-4):216-226.
PMID: 35073541
Introduction: The interindividual variability of the antiplatelet effect of clopidogrel is determined by multiple clinical and genetic factors. A lot of genotype-oriented studies have concentrated on the impact of CYP2C19...
4.
Sychev D, Mirzaev K, Cherniaeva M, Kulikova M, Bochkov P, Shevchenko R, et al.
Drug Metab Pers Ther
. 2020 Sep;
35(3).
PMID: 32975202
Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate...
5.
Sychev D, Mirzaev K, Cherniaeva M, Kulikova M, Bochkov P, Shevchenko R, et al.
Drug Metab Pers Ther
. 2020 Sep;
PMID: 32887180
Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate...
6.
Skripka A, Sychev D, Bochkov P, Shevchenko R, Krupenin P, Kogay V, et al.
High Blood Press Cardiovasc Prev
. 2020 Mar;
27(2):151-156.
PMID: 32215878
Introduction: Dabigatran is effective and widely used to prevent ischemic stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). Chronic kidney disease (CKD) also has implications for choice...
7.
Sychev D, Skripka A, Ryzhikova K, Bochkov P, Shevchenko R, Krupenin P, et al.
Drug Metab Pers Ther
. 2020 Mar;
35(1).
PMID: 32134727
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD). The study assessed whether...
8.
Sychev D, Minnigulov R, Bochkov P, Ryzhikova K, Yudina I, Lychagin A, et al.
High Blood Press Cardiovasc Prev
. 2019 Oct;
26(5):413-420.
PMID: 31617197
Introduction: Population ageing in developed countries will inevitably increase the need for knee and hip replacement surgery. Over the years, direct oral anticoagulants, such as rivaroxaban, have been widely used...